Portal de Periódicos da CAPES

EGFR Antibodies in Colorectal Cancer: Where Do They Belong?

2010; Lippincott Williams & Wilkins; Volume: 28; Issue: 31 Linguagem: Inglês

10.1200/jco.2010.29.3407

1527-7755

Axel Grothey,

Genetic factors in colorectal cancer

cancer.First, radiotherapy combined with neoadjuvant hormonal therapy resulted in a survival advantage over external radiation without neoadjuvant hormone treatment in a European trial as well as in a subsequent trial in the United States. 9,10Second, prostatectomy resulted in a survival advantage over watchful waiting (with the latter often accompanied by later radiotherapy or hormonal therapy) in the Swedish Scandinavian Prostatic Cancer Group (SPCG)-4 trial. 11Third, external-beam radiation combined with neoadjuvant hormonal therapy led to a survival advantage over hormonal therapy alone in a European trial. 12Therefore, the HRQOL detriments of external radiation monotherapy or brachytherapy monotherapy observed by Pardo et al may reduce enthusiasm for these two primary radiotherapy treatment options for which class I evidence of survival benefit, in the absence of concurrent androgen deprivation, remains elusive.